Company intelligence / Profile preview
Medera Inc.
Boston, MA, United Statesmedera.bio ↗
- Ownership
- Public · KVAC
- Development stage
- Other
01
Overview
Medera has three ongoing AAV-based cardiac gene therapy clinical trials. SRD-002 for HFpEF has demonstrated promising Phase 1/2 efficacy and safety, with plans to initiate a pivotal trial by the end of 2025. SRD-001 for HFrEF is in Phase 1/2 trials with completion expected in Q4 2025. SRD-003 for DMD-CM is in Phase 1/2 trials with interim data expected in mid-2026. The company has received Fast Track Designation for its HFpEF program and Orphan Drug Designation for its DMD-CM program.
- Therapeutic areas
- PulmonologyCardiovascular
- Modalities
- Gene therapyCell therapySmall molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Medera Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medera Inc..